All In Biotech

Drug Trial Radar · NCT01780506

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Last checked: Nov 19, 2026Latest source record: Nov 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 872 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

872

Actual

Start

Dec 26, 2012

Primary completion

Aug 26, 2014

Study completion Sep 6, 2017

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jan 31, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.

Conditions

  • HIV
  • HIV Infections

Interventions

  • E/C/F/TAFDrug

    150/150/200/10 mg FDC tablet administered orally once daily

  • E/C/F/TDFDrug

    150/150/200/300 mg FDC tablet administered orally once daily

  • E/C/F/TDF PlaceboDrug

    Tablet administered orally once daily

  • E/C/F/TAF PlaceboDrug

    Tablet administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48

Locations

117 sites in 12 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Spectrum Medical Group

    Phoenix, Arizona

  • Kaiser Permanente Los Angeles

    Los Angeles, California

  • University of California, Los Angeles

    Los Angeles, California

  • Peter J. Ruane, MD, Inc.

    Los Angeles, California

  • Anthony Mills MD Inc

    Los Angeles, California

  • East Bay AIDS Center

    Oakland, California

  • Kaiser Permanente - Sacramento

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • University of California, San Diego

    San Diego, California

  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

    Torrance, California

  • Apex Research, LLC

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Dupont Circle Physicians Group, P.C.

    Washington D.C., District of Columbia

  • Whitman Walker Clinic

    Washington D.C., District of Columbia

  • Capital Medical Associates, P.C.

    Washington D.C., District of Columbia

  • Gary Richmond, MD, PA, Inc.

    Fort Lauderdale, Florida

  • Midway Immunology & Research Center, LLC

    Ft. Pierce, Florida

  • The Kinder Medical Group

    Miami, Florida

  • AIDS Healthcare Foundation

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • IDOCF/ValuHealthMD, LLC

    Orlando, Florida

  • Infectious Diseases Associates

    Pensacola, Florida

  • The University of South Florida

    Tampa, Florida

  • Infectious Disease Research Institute Inc.

    Tampa, Florida

  • St. Joseph's Comprenhensive Research Inisitute

    Tampa, Florida

  • AIDS Research and Treatment Center of the Treasure Coast

    Vero Beach, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • Emory University

    Atlanta, Georgia

  • Atlanta ID Group, PC

    Atlanta, Georgia

  • Infectious Disease Specialist of Atlanta

    Decatur, Georgia

  • Mercer University School of Medicine

    Macon, Georgia

  • University of Hawaii - Hawaii Center for AIDS

    Honolulu, Hawaii

  • Northwestern University

    Chicago, Illinois

  • Ruth M. Rothstein CORE Center

    Chicago, Illinois

  • Howard Brown Health Center

    Chicago, Illinois

  • Institute of Human Virology, University of Maryland

    Baltimore, Maryland

  • Community Research Initative

    Boston, Massachusetts

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Metrowest Medical Center

    Framingham, Massachusetts

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.